An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...

Just a month after laying off 147 employees and announcing plans to mull “strategic alternatives,” Vor Biopharma Inc.

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.

Abvance Therapeutics Inc. secured an undisclosed amount of capital in a seed round led by Zubi Capital to support development ...

Edgewise Therapeutics Inc. CEO Kevin Koch speculated that “perhaps a different environment at the FDA” from four months ago ...

Innovent Biologics Inc. announced a HKD$4.3 billion (US$547 million) placement on the Hong Kong Stock Exchange to advance its R&D projects and to fund its global expansion.

Mira Pharmaceuticals Inc. has reported new in vitro preclinical data supporting the therapeutic potential of SKNY-1, a ...

B4, to its pipeline for prevention of group A Streptococcus (GAS) infections. Invasive GAS infections can cause diseases such ...

Novo Nordisk A/S recently presented data regarding their antibody fragment Inno-8 for the potential treatment of hemophilia A ...